Motley Fool Wealth Management LLC Sells 13,220 Shares of Novo Nordisk A/S $NVO

Motley Fool Wealth Management LLC trimmed its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 14.7% during the second quarter, Holdings Channel.com reports. The institutional investor owned 76,618 shares of the company’s stock after selling 13,220 shares during the quarter. Motley Fool Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $5,288,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of NVO. Kingstone Capital Partners Texas LLC boosted its holdings in shares of Novo Nordisk A/S by 301,443.6% during the 2nd quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company’s stock worth $690,560,000 after buying an additional 10,001,898 shares in the last quarter. Nuveen LLC bought a new position in shares of Novo Nordisk A/S in the 1st quarter worth $370,272,000. Amundi lifted its holdings in shares of Novo Nordisk A/S by 49.1% in the 1st quarter. Amundi now owns 4,938,507 shares of the company’s stock worth $331,576,000 after purchasing an additional 1,627,051 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in shares of Novo Nordisk A/S by 15,919.9% in the 1st quarter. Acadian Asset Management LLC now owns 1,044,658 shares of the company’s stock worth $72,523,000 after purchasing an additional 1,038,137 shares in the last quarter. Finally, DAVENPORT & Co LLC lifted its holdings in shares of Novo Nordisk A/S by 61.1% in the 1st quarter. DAVENPORT & Co LLC now owns 1,695,522 shares of the company’s stock worth $117,682,000 after purchasing an additional 642,810 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

NVO has been the topic of a number of recent research reports. Hsbc Global Res upgraded Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 1st. Jefferies Financial Group initiated coverage on Novo Nordisk A/S in a report on Monday. They issued an “underperform” rating on the stock. Barclays reiterated an “equal weight” rating on shares of Novo Nordisk A/S in a report on Wednesday, July 30th. Berenberg Bank upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Wednesday, September 17th. Finally, UBS Group cut Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a report on Tuesday, August 5th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Hold” and a consensus target price of $76.00.

Novo Nordisk A/S Trading Down 0.1%

NYSE NVO opened at $52.92 on Tuesday. The firm has a market capitalization of $236.27 billion, a P/E ratio of 14.54, a PEG ratio of 2.41 and a beta of 0.68. The business has a fifty day simple moving average of $56.55 and a 200 day simple moving average of $62.29. Novo Nordisk A/S has a 12 month low of $45.05 and a 12 month high of $113.76. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.93 by $0.04. The business had revenue of $11.69 billion during the quarter, compared to analyst estimates of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. On average, analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were given a dividend of $0.4119 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 22.53%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.